AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Ischemic heart disease still represents a large burden on individuals and health care
resources worldwide. By conventions, it is equated with atherosclerotic plaque due to flow …

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from
anticancer medications and represents an important limitation for the use of antithrombotic …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the
population have led to an increasing number of cancer patients presenting with acute CV …

Atrial fibrillation (AF) is the most frequent chronic arrhythmia worldwide, and it is associated
with significant morbidity and mortality, making it a considerable burden both to patients and …

Noncompaction cardiomyopathy (NCCM) is a rare condition characterized by prominent
trabeculae, deep intertrabecular recesses, and a left ventricular myocardium with a two …

Abstract Purpose of Review To provide an update on epidemiology, risk factors, and
management of cardiac arrhythmias in oncological patients within the context of the new …